A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients.

Ann Rheum Dis · 2014 · PMC3888620 · PMID 23434567

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Preliminary results indicate a positive trend between target neutralisation of the IFNGS and reduction in disease activity in dermatomyositis or polymyositis patients, an observation that needs additional confirmation.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.